Yamachika Eiki, Matsubara Masakazu, Ikeda Atsushi, Matsumura Tatsushi, Moritani Norifumi, Iida Seiji
Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Hospital, Okayama, Japan.
J Craniofac Surg. 2015 Oct;26(7):e575-7. doi: 10.1097/SCS.0000000000002127.
The definition of bisphosphonate-related osteonecrosis of the jaw (BRONJ) was recently broadened and it is now known as medication-related osteonecrosis of the jaw (MRONJ). To date, the management of MRONJ is controversial. Conservative treatment is recommended, but it is difficult to successfully treat stage 3 MRONJ. Administration of teriparatide for the MRONJ treatment has only been documented in independent case reports and there are few reports on men with MRONJ treated with teriparatide. An 81-year-old man was referred in May 2014 for treatment of an unhealed tooth extraction wound in the mandible. He took minodronic acid hydrate (1 mg/d orally) for 2 years because of osteoporosis cure. On clinical examination, soft tissue swelling in the left mandibular first molar region extended to the inferior border of the mandible with extraoral fistula. Computed tomography (CT) revealed osteolysis extending to the inferior border resulting in pathologic fracture of mandibular bone. Based on these findings, a diagnosis of stage 3 MRONJ was made. We performed conservative treatment, including amoxicillin, but his symptoms did not improve. He was then treated with once-weekly subcutaneous injection of teriparatide. Although teriparatide injections were started without antibiotics, after 1 week, swelling, erythema, and purulent discharge from the extraoral fistula increased rapidly. Therefore, we combined the once-weekly teriparatide injection with amoxicillin administration. Three months later, the osteonecrosis had healed and CT showed significant bone regeneration and healing of the mandibular pathologic fracture. In addition, the mandibular fistula showed healing and the intraoral fistula was covered with normal mucosa.
双膦酸盐相关颌骨坏死(BRONJ)的定义最近有所拓宽,现在被称为药物相关颌骨坏死(MRONJ)。迄今为止,MRONJ的治疗存在争议。推荐采用保守治疗,但3期MRONJ难以成功治愈。关于特立帕肽用于MRONJ治疗仅有独立的病例报告,且鲜有关于男性MRONJ患者接受特立帕肽治疗的报道。一名81岁男性于2014年5月因下颌骨拔牙创未愈合前来就诊。因其骨质疏松症治愈,他口服米诺膦酸水合物(1毫克/天)达2年。临床检查发现,左下颌第一磨牙区软组织肿胀延伸至下颌下缘并伴有口外瘘管。计算机断层扫描(CT)显示骨质溶解延伸至下颌下缘,导致下颌骨病理性骨折。基于这些发现,诊断为3期MRONJ。我们进行了包括阿莫西林在内的保守治疗,但他的症状并未改善。随后他接受了每周一次的皮下注射特立帕肽治疗。尽管在未使用抗生素的情况下开始注射特立帕肽,但1周后,口外瘘管的肿胀、红斑及脓性分泌物迅速增多。因此,我们将每周一次的特立帕肽注射与阿莫西林给药联合应用。3个月后,骨坏死已愈合,CT显示下颌骨有显著的骨再生及病理性骨折愈合。此外,下颌瘘管愈合,口内瘘管被正常黏膜覆盖。